Celltech Group plc, of Slough, UK, said partner Pharmacia Corp., of Peapack, N.J., completed reformulation of Celltech's CDP 870 and that Phase III development in rheumatoid arthritis will begin next month. The move into Phase III will trigger a milestone payment to Celltech. Celltech also is developing CDP 870, a humanized, pegylated anti-TNF-alpha antibody fragment, in Crohn's disease, and CEO Peter Fellner said planning for Phase III studies in Crohn's is under way. However, the exact timing will depend on the availability of the drug, with priority going to supplying the Pharmacia-run rheumatoid arthritis trials.
F2G Ltd., of Manchester, UK, confirmed the completion of its first-round funding, raising [pounds sterling]4.3 million (US$6.7 million). The company will use the money to take on more staff and expand drug discovery efforts based around Mycobank, its functional genomics technology for the rapid identification of genes that are essential for fungi to survive. F2G is particularly focused on finding new treatments for Aspergillus infections.
IT-Omics, the bioinformatics subsidiary of Lille, France-based Genfit SA, entered a technical partnership with the life sciences division of IBM Corp. in France for the development of data manipulation and analysis software based on the DiscoveryLink platform that IBM developed specifically for life sciences research. DiscoveryLink is derived from IBM's DB2 database management system and enables researchers to handle and analyze heterogeneous data simultaneously from their …
No comments:
Post a Comment